• Envíos a toda la península en 24-48h.

Efecto protector de la curcumina contra la lesión de la mucosa intestinal inducida por irinotecán a través de la atenuación de la activación de NF-B, estrés oxidativo y estrés retículo endoplasmático

Abstract Irinotecan (CPT‑11) is a DNA topoisomerase I inhibitor which is widely used in clinical chemotherapy, particularly for colorectal cancer treatment. However, late‑onset diarrhea is one of the severe side‑effects of this drug and this restricts its clinical application. The present study aimed to investigate the protective effects of curcumin treatment on CPT‑11‑induced intestinal mucosal injury both in vitro and in vivo and to elucidate the related mechanisms involved in these effects. For this purpose, mice were intraperitoneally injected with CPT‑11 (75 mg/kg) for 4 days to establish a model of late‑onset diarrhea. Curcumin (100 mg/kg) was intragastrically administered 8 days before the injection of CPT‑11. Injury to small intestinal tissues was examined by H&E staining. The protein expression of

Avances en la investigación del efecto protector de la curcumina en la función de barrera mucosa intestinal

Abstract As a natural extract from turmeric, curcumin has extensive pharmacological effects, such as anti-tumor, anti-inflammation, anti-oxidative stress, anti-microbial, immunoregulation and so on. In recent years, an increasing number of basic and clinical researches have shown that curcumin takes therapeutic effects on various diseases, such as gastrointestinal diseases, cardiovascular diseases, autoimmune diseases, neuropsychiatric diseases and so on. Many of the pharmacological effects and mechanisms of curcumin are associated with protective effects of intestinal mucosal barrier. It can protect intestinal mucosal barrier through mutiple pathways, including anti-inflammation, anti-oxidative stress, anti-bacterial, anti-apoptosis, regulating intestinal microecology and intestinal immune response and so on. This paper summarizes the protective effects of curcumin on intestinal barrier function and the mechanism, in order to provide new

La curcumina y el resveratrol regulan las bacterias intestinales y alivian la inflamación intestinal en lechones destetados

Abstract Human infants or piglets are vulnerable to intestinal microbe-caused disorders and inflammation due to their rapidly changing gut microbiota and immaturity of their immune systems at weaning. Resveratrol and curcumin have significant anti-inflammatory, bacteria-regulating and immune-promoting effects. The purpose of this study was to investigate whether dietary supplementation with resveratrol and curcumin can change the intestinal microbiota and alleviate intestinal inflammation induced by weaning in piglets. One hundred eighty piglets weaned at 21 ± 2 d were fed a control diet (CON group) or supplemented diet (300 mg/kg of antibiotics, ANT group; 300 mg/kg of resveratrol and curcumin, respectively, HRC group; 100 mg/kg of resveratrol and curcumin, respectively, LRC group; 300 mg/kg of resveratrol, RES group; 300 mg/kg of

La curcumina mejora la función de barrera intestinal: modulación de la señalización intracelular y organización de uniones estrechas

Abstract Association between circulating lipopolysaccharide (LPS) and metabolic diseases (such as type 2 diabetes and atherosclerosis) has shifted the focus from high-fat high-cholesterol containing Western-type diet (WD)-induced changes in gut microbiota per se to release of gut bacteria-derived products (e.g., LPS) into circulation due to intestinal barrier dysfunction as the possible mechanism for the chronic inflammatory state underlying the development of these diseases. We demonstrated earlier that oral supplementation with curcumin attenuates WD-induced development of type 2 diabetes and atherosclerosis. Poor bioavailability of curcumin has precluded the establishment of a causal relationship between oral supplementation and it is in vivo effects. We hypothesized that curcumin attenuates WD-induced chronic inflammation and associated metabolic diseases by modulating the function of intestinal epithelial

Curcumina y Enfermedades Inflamatorias Intestinales: Mecanismos Moleculares de Protección

Abstract Objective: To investigate the anti-ulcerative colitis mechanism of resveratrol through regulation of Wnt/β-catenin signaling pathway. Intestinal inflammatory diseases, such as Crohn’s disease, ulcerative colitis, and necrotizing enterocolitis, are becoming increasingly prevalent. While knowledge of the pathogenesis of these related diseases is currently incomplete, each of these conditions is thought to involve a dysfunctional, or overstated, host immunological response to both bacteria and dietary antigens, resulting in unchecked intestinal inflammation and, often, alterations in the intestinal microbiome. This inflammation can result in an impaired intestinal barrier allowing for bacterial translocation, potentially resulting in systemic inflammation and, in severe cases, sepsis. Chronic inflammation of this nature, in the case of inflammatory bowel disease, can even spur cancer growth in the longer-term. Recent

Efectos del resveratrol en la colitis ulcerosa en ratones y su mecanismo

Abstract Objective: To investigate the anti-ulcerative colitis mechanism of resveratrol through regulation of Wnt/β-catenin signaling pathway. Methods: ①The experiment of ulcerative colitis induced by dextran sulfate sodium salt (DSS): 28 C57BL/6 mice were randomly divided into four groups including control group(n=7), DSS group(n=7), DSS+Resveratrol (DSS+Res) group(n=7) and Res group(n=7). The experiment lasted for 3 weeks. Ulcerative colitis of mice was induced by drinking DSS water and treated with resveratrol by intragastric administration. The mice were weighed daily and their activities and state of feces were recorded. After that, the mice were euthanized, the spleens were weighed, and the colonic length was measured.Hematoxylin-eosin staining (HE) was used to observe the pathological changes of the colon, and the expression of miR-31 in colonic tissue

Las interacciones bidireccionales entre Resveratrol y Gut Microbiota: Una visión sobre el estrés oxidativo y la terapia inflamatoria de la enfermedad intestinal

Abstract Dysbiosis and oxidative stress in the gut have contributed to the progression of intestinal inflammatory bowel disease (IBD). The current study has reported that enteric bacteria mediate redox homeostasis through the regulation of reactive oxygen species (ROS) production. Resveratrol, one of the most abundant polyphenols, with poor oral bioavailability, is considered as a scavenger of ROS and other free radicals. Recent studies have shown that resveratrol effectively enhances the growth of Lactococcus lactis and inhibits the growth of Enterococcus faecalis. (1) In terms of the two-way relationship between gut microbiota and resveratrol, resveratrol modulates gut microbiota; (2) in terms of resveratrol biotransformation by gut microbiota, we speculate that gut microbiota could be a target of resveratrol to maintain gut homeostasis. Here, we

Resveratrol y enfermedad inflamatoria intestinal

Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, comprising ulcerative colitis (UC) and Crohn’s disease (CD). Progression of IBD leads to long-term impairment of intestinal structure and function. The pathogenesis of IBD is complex, involving environmental, immunological, genetic, microbial, and psychological factors. The conventional therapies and many existing biopharmaceuticals for IBD have limited efficacy or adverse effects. As a promising safe and effective therapy for IBD, resveratrol has been studied widely, as it has shown anti-inflammatory and antioxidant activity. Resveratrol’s mechanism of action involves multiple immune responses and signaling pathways; it is absorbed quickly and metabolized into various derivatives. However, the poor water solubility and low bioavailability of resveratrol limit its clinical applications. Further

Beneficios para la salud del resveratrol: Evidencia de estudios clínicos

Abstract Resveratrol is a polyphenolic nutraceutical that exhibits pleiotropic activities in human subjects. The efficacy, safety, and pharmacokinetics of resveratrol have been documented in over 244 clinical trials, with an additional 27 clinical trials currently ongoing. Resveretrol is reported to potentially improve the therapeutic outcome in patients suffering from diabetes mellitus, obesity, colorectal cancer, breast cancer, multiple myeloma, metabolic syndrome, hypertension, Alzheimer’s disease, stroke, cardiovascular diseases, kidney diseases, inflammatory diseases, and rhinopharyngitis. The polyphenol is reported to be safe at doses up to 5 g/d, when used either alone or as a combination therapy. The molecular basis for the pleiotropic activities of resveratrol are based on its ability to modulate multiple cell signaling molecules such as cytokines, caspases, matrix metalloproteinases,

Resveratrol, Síndrome Metabólico y Microbiota intestinal

Abstract Resveratrol is a polyphenol which has been shown to have beneficial effects on metabolic syndrome-related alterations in experimental animals, including glucose and lipid homeostasis improvement and a reduction in fat mass, blood pressure, low-grade inflammation, and oxidative stress. Clinical trials have been carried out to address its potential; however, results are still inconclusive. Even though resveratrol is partly metabolized by gut microbiota, the relevance of this “forgotten organ” had not been widely considered. However, in the past few years, data has emerged suggesting that the therapeutic potential of this compound may be due to its interaction with gut microbiota, reporting changes in bacterial composition associated with beneficial metabolic outcomes. Even though data is still scarce and for the most

Cargar más

Últimas Entradas

Más información

Ayuda y soporte

  • Síguenos en:
Vimeo Facebook Instagram

Natural Probiotics 2023 © Todos los derechos reservados.

  • Compra segura

Natural Probiotics 2023 © Todos los derechos reservados.

  • Compra segura

¡GRACIAS!

Solicitud  RECIBIDA

En el plazo de 24-48 horas nos pondremos en contacto con ud. para informarle y facilitarle sus datos de acceso.

Explorar productos
ir a inicio

CONCENTIMIENTO

Política de privacidad

En la presente Política de Privacidad, le informamos sobre la recopilación, tratamiento y uso de sus datos personales recabados por Natural Probiotics S.L.. mediante la utilización de la presente página web.

Responsable del tratamiento:

Identidad: Natural Probiotics S.L.

Domicilio social: Passeig Irlanda 16, Local Bajo., 08030, Barcelona

C.I.F. nº: B67286245

Email: privacidad@naturalprobiotics.es

Tras la lectura del presente documento y /o con la aceptación de nuestras condiciones de servicios en el proceso de registro como cliente particular o profesional consiente el tratamiento de sus datos para las finalidades que se detallarán a continuación por parte de Natural Probiotics.

De conformidad con lo establecido en los arts. 6.1.a), 7 Y 8 del REGLAMENTO (UE) 2016/679 DEL PARLAMENTO EUROPEO Y DEL CONSEJO de 27 de abril de 2016, relativo a la protección de las personas físicas en lo que respecta al tratamiento de datos personales le comunicamos que los datos que usted nos facilite quedarán incorporados y serán tratados en los ficheros titularidad del responsable del tratamiento Natural Probiotics S.L..

¿Por qué y para qué tratamos tus datos?

En Natural Probiotics tratamos la información que nos facilitan las personas interesadas con las siguientes finalidades:

Gestionar pedidos o contratar alguno de nuestros servicios, ya sea online o en las tiendas físicas.

Gestionar el envío de la información que nos soliciten.

Desarrollar acciones comerciales y realizar el mantenimiento y gestión de la relación con el usuario.

¿Cuál es la legitimación para el tratamiento de tus datos?

 

El tratamiento de tus datos puede fundamentarse en las siguientes bases legales:

Ejecución de un contrato o en la prestación de un servicio en base a una relación comercial que cuenta con el consentimiento del interesado.

Interés legítimo para el envío de información comercial sobre productos y servicios (marketing directo).

Interés legítimo para el contacto y mantenimiento de la relación con clientes y proveedores.

Cumplimiento de obligaciones legales para prevención del fraude, comunicación con Autoridades públicas y reclamaciones de terceros.

Consentimiento explícito del usuario para la elaboración de perfiles, los formularios de contacto, las solicitudes de información o alta en e-newsletters.

¿A qué destinatarios se comunican sus datos?

En algunos casos, solo cuando sea necesario, Natural Probiotics proporcionará datos de los usuarios a terceros. Sin embargo, nunca se venderán los datos a terceros. Los proveedores de servicios externos (por ejemplo, proveedores de pago o empresas de reparto) con los que Natural Probiotics trabaje pueden usar los datos para proporcionar los servicios correspondientes, sin embargo no usarán dicha información para fines propios o para cesión a terceros. Dichos proveedores tienen la obligación de garantizar que la información se trata conforme con la normativa de privacidad de datos.

En algunos casos, la ley puede exigir que se revelen datos personales a organismos públicos u otras partes, solo se revelará lo estrictamente necesario para el cumplimiento de dichas obligaciones legales.

Los datos personales obtenidos también podrán ser compartidos con otras empresas del grupo.

¿Qué derechos le asisten y cómo puede ejercerlos?

Puede dirigir sus comunicaciones y ejercitar sus derechos mediante una petición en el siguiente correo electrónico: privacidad@naturalprobiotics.es. En virtud de lo que establece el RGPD puedes solicitar derecho de acceso, derecho de rectificación, derecho de supresión y al olvido, derecho de limitación al tratamiento, derecho de oposición, derecho a la portabilidad y derecho a no ser objeto de decisiones individualizadas.